Vaxart (NASDAQ:VXRT) is a biotechnology company focused on developing oral recombinant vaccines based on its proprietary delivery platform. Vaxart's vaccine candidates target a variety of infectious diseases including influenza, norovirus, and coronavirus (COVID-19), aiming to offer an alternative to traditional injection-based vaccines through their tablet formulations. This innovative approach seeks not only to improve the ease of administration but also to enhance patient compliance and potentially broaden vaccine coverage globally. With a commitment to public health, Vaxart’s projects are geared towards producing effective, accessible, and convenient vaccine options. Their objectives center on advancing the clinical development of their vaccine candidates, expanding their vaccine portfolio, and making a significant impact on preventing infectious diseases.